Table 6.
Short-term results of phase II and of retrospective available studies
| Author ( a Study) |
N. of patients | Stage | Radiotherapy | Compliance RT-CT | pCR | Tox ≥ 3 | Post-op morbidity |
|---|---|---|---|---|---|---|---|
| De Ridder et al. [24] (Phase II) |
24/13 | T3-T4 MRF+ |
46Gy/23fr/2 SIB 55.2Gy/23fr/2.4Gyfr |
100% -noCT | 14% | 4.2% | 8% |
| Li et al. [25] (Phase II) |
63 | T3-T4 N+ |
41.8Gy/22fr/1.9 SIB 50.6Gy/22fr/2.3Gyfr |
100% –100% | 31% | 14% | 7% |
| Hernando et al. [26] (Retrospective) |
74 | T2-T4 N+ |
45Gy/25fr/1.8 SIB 57.5Gy/25fr/2.3Gyfr |
99% – 99% | 31% | 17.6% | 7% |
| Zhu et al. [27] (Phase II) |
78 | T3-T4 N0/N+ |
50Gy/25fr/2 SIB 55Gy/25fr/2.2Gyfr |
100% – 62% | 24% | 14% | 17% |
| Wang et al. [28] (Retrospective) |
260 | T3-T4- N0/N+ |
41.8Gy/22fr/1.9 SIB 50.6Gy/22fr/2.3Gyfr |
99% – 99% | 18.5% | 6% | 23% |
|
bArbea et al. [29] (Phase II) |
100 | T3-T4 N+ |
47.5Gy/19fr/2.5 and
47.5Gy/20fr/2.4Gyfr |
97% – 80% | 13% | 25% | 7% |
| Our experience | 76 | T3-T4 N0/N+ |
45 Gy/25fr/1.8 SIB 52.5–57.Gy/25fr 2.1–2.3Gyfr |
97.4% – 84% | 22% | 10.5% | 18% |
aAll Studies included concurrent Capecitabine bConcurrent Capecitabine-Oxaliplatin